search
Back to results

Perception of Facial Emotions in Schizophrenia and 22q11 Deletion Syndrome (FaSchi22)

Primary Purpose

Schizophrenia

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
schizophrenia
the 22q11 deletion syndrome
control group
Sponsored by
Hôpital le Vinatier
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Schizophrenia focused on measuring schizophrenia, Facial emotions

Eligibility Criteria

15 Years - 50 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Aged 15-50 years old
  • No psychiatric conditions or comorbidity
  • Agreement from parents if participant is underage
  • Patients with schizophrenia: diagnosis assessed with DSM5 criteria
  • Patients with 22q11.2 DS: diagnosis assessed by genetic tests (CGH- array or FISH)
  • No mental delay (IQ>70 according to the fNART)
  • No modification of psychotropic treatment during the month before inclusion

Exclusion Criteria:

  • Involvement in a current program of social cognition remediation
  • Pregnancy
  • Substance use disorder (criteria of DSM-5), except for caffeine and tobacco
  • Neurologic disorders (vascular, infectious or neurodegenerative)
  • Uncorrected visual deficit
  • Guardianship
  • Medical drugs with cerebral or psychological effect (e.g, corticosteroids)
  • Resistance to antipsychotics
  • Electroconvulsive therapy in the previous two months

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Other

    Other

    Arm Label

    22Q11

    SCHIZOPHRENIA

    Arm Description

    24 patients with 22Q11DS to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.

    24 patients with schizophrenia to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.

    Outcomes

    Primary Outcome Measures

    Steady-state visual evoked potentials (SSVEP) recorded during fast periodic visual stimulation (FPVS).
    SSVEPs arise in response to the periodic presentation of emotional faces. They are analyzed in the frequency domain. Two types of responses are expected: the general visual response (6 Hz and its harmonics) and the expression-specific response (1.2 Hz and its harmonics). Both responses will be compared across the different groups.

    Secondary Outcome Measures

    Full Information

    First Posted
    December 16, 2015
    Last Updated
    February 7, 2018
    Sponsor
    Hôpital le Vinatier
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02634671
    Brief Title
    Perception of Facial Emotions in Schizophrenia and 22q11 Deletion Syndrome
    Acronym
    FaSchi22
    Official Title
    Facial Expression Perception by Intensity in Schizophrenia and 22q11.2 Deletion Syndrome: Neural Electrophysiological Evidence by Means of Fast Periodic Visual Stimulation
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    November 2015 (undefined)
    Primary Completion Date
    October 20, 2017 (Actual)
    Study Completion Date
    December 30, 2017 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Hôpital le Vinatier

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Background: The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia and the 22q11.2 deletion syndrome, and thus, reveal a distinction between the two disorders. Indeed, despite the clinical overlap between the two syndromes, some of the symptoms appear to be specific to only one of them. In particular, the disturbance of visual functions is specifically observed in the 22q11.2DS. Hence, the difficulties in facial emotion recognition in schizophrenia and in the 22q11.DS are likely accounted by different cognitive impairments. Investigating which mechanisms are disturbed would allow a specialized support for patients. Our main hypothesis is that the deficit in facial emotion recognition is more related to visual impairments in the 22q11.2DS than in schizophrenia. This hypothesis will be tested in two groups of patients (22q11.2DS and schizophrenic patients) and a control group (healthy subjects) using an experimental paradigm based on electroencephalography (EEG). A second aim of this study is to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.
    Detailed Description
    Methods: This study will be conducted using visual steady-state visual evoked potentials (SSVEPs). Visual SSVEPs are periodic neural electrophysiological activities that arise in response to fast periodic visual stimulation (FPVS). They will be recorded in response to the periodic presentation of faces, according to an oddball paradigm. While pictures of faces will appear at a 6 Hz rate, only 1 out of 5 will display an emotion, corresponding to a 1.2 Hz oddball frequency. Different emotions will be tested (happiness, sadness, anger, fear and disgust), displayed with different intensities (20%, 60%, 100%). SSVEPs at 6 Hz will reflect general visual mechanisms (in response to a mixture of low-level (i.e., contrast coding) and high-level (i.e., face detection) processes). Importantly, SSVEPs at 1.2 Hz will index the visual mechanisms specifically involved in facial expression perception and their sensitivity to emotion intensity. Both measures will help determine the underlying brain topographies. Alongside, clinical and neuropsychological tests will be conducted. While the clinical tests will evaluate the severity of the symptoms, the neuropsychological tests will assess different features such as attention, memory, verbal and visuo-spatial abilities. The patients' scores will be linked with their cerebral activity in response to facial expressions. Outcomes: To better understand the impairment of facial emotion recognition in schizophrenia and 22q11.2DS and to improve its care.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Schizophrenia
    Keywords
    schizophrenia, Facial emotions

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    70 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    22Q11
    Arm Type
    Other
    Arm Description
    24 patients with 22Q11DS to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.
    Arm Title
    SCHIZOPHRENIA
    Arm Type
    Other
    Arm Description
    24 patients with schizophrenia to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.
    Intervention Type
    Other
    Intervention Name(s)
    schizophrenia
    Intervention Description
    The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia with a control group using an experimental paradigm based on electroencephalography (EEG)
    Intervention Type
    Other
    Intervention Name(s)
    the 22q11 deletion syndrome
    Intervention Description
    The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
    Intervention Type
    Other
    Intervention Name(s)
    control group
    Intervention Description
    The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the schizophrenia and 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
    Primary Outcome Measure Information:
    Title
    Steady-state visual evoked potentials (SSVEP) recorded during fast periodic visual stimulation (FPVS).
    Description
    SSVEPs arise in response to the periodic presentation of emotional faces. They are analyzed in the frequency domain. Two types of responses are expected: the general visual response (6 Hz and its harmonics) and the expression-specific response (1.2 Hz and its harmonics). Both responses will be compared across the different groups.
    Time Frame
    SSVEPs will be recorded during 20 sequences of emotional faces pictures. As each sequence lasts 80s, the EEG recording will be approximately 30-minutes-long.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    15 Years
    Maximum Age & Unit of Time
    50 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Aged 15-50 years old No psychiatric conditions or comorbidity Agreement from parents if participant is underage Patients with schizophrenia: diagnosis assessed with DSM5 criteria Patients with 22q11.2 DS: diagnosis assessed by genetic tests (CGH- array or FISH) No mental delay (IQ>70 according to the fNART) No modification of psychotropic treatment during the month before inclusion Exclusion Criteria: Involvement in a current program of social cognition remediation Pregnancy Substance use disorder (criteria of DSM-5), except for caffeine and tobacco Neurologic disorders (vascular, infectious or neurodegenerative) Uncorrected visual deficit Guardianship Medical drugs with cerebral or psychological effect (e.g, corticosteroids) Resistance to antipsychotics Electroconvulsive therapy in the previous two months
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    DEMILY CAROLINE, PH
    Organizational Affiliation
    Centre régional de dépistage et de prises en charge des troubles psychiatriques d'origine génétique Pôle Ouest LE VINATIER HOSPITAL
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Perception of Facial Emotions in Schizophrenia and 22q11 Deletion Syndrome

    We'll reach out to this number within 24 hrs